Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13420777 | 0.91 | NOTUM (0.72) | NOTUM | |
| SCHEMBL17026816 | 0.84 | NOTUM (0.54) | NOTUMATMTRPV1 | |
| SCHEMBL1573274 | 0.83 | NOTUM (0.83) | NOTUM | |
| SCHEMBL3449455 | 0.82 | NOTUM (0.60) | NOTUMKDM4EHSD17B10 | |
| SCHEMBL14321700 | 0.82 | PDK2 (0.51) | NOTUMTRPV1PDK2NPY5R | |
| SCHEMBL23380315 | 0.82 | MAPT (0.53) | NOTUMTRPV1KDM4EPDK2NPY5R | |
| SCHEMBL6313563 | 0.82 | NOTUM (0.56) | NOTUMKDM4ECYP2C19PDK2 | |
| SCHEMBL1222301 | 0.81 | NOTUM (0.79) | NOTUMKDM4ECYP2C19 | |
| SCHEMBL5799166 | 0.81 | NOTUM (0.58) | NOTUMTRPV1KDM4ECYP2C19PDK2 | |
| SCHEMBL5800964 | 0.81 | NOTUM (0.83) | NOTUMTRPV1KDM4EUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | claimed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| WO-2023177700-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-103748093-B | Imidazopyridyl-the aminopyridine compounds being replaced | ARQULE, INC. (US) | 2016-06-01 | — | — | CN | disclosed |
| EP-2723741-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2723741-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| CN-103748093-A | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE INC | 2014-04-23 | — | — | CN | disclosed |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. | 2014-03-13 | — | — | US | disclosed |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. | 2014-03-13 | — | — | US | disclosed |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. | 2014-03-13 | — | — | US | disclosed |
| US-8609688-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012177844-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | NOTUM 3885/4885PPARG 813/4885ATM 1305/4885 |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | NOTUM 3885/4885PPARG 813/4885ATM 1305/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | NOTUM 3548/4885PPARG 1149/4885ATM 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.